Novigenix Collaborates with BioLizard to Develop AI-Based Diagnostic Algorithm for Detecting Colon Cancer
Shots:
- BioLizard to develop an AI-based bioinformatics algorithm supporting the transition of its Immuno-Transcriptomic RT-PCR based product- Colox onto Novigenix’s LITOseek platform for early colon cancer detection as well as with other products under development
- The collaboration involves BioLizard expertise in bioinformatics- machine learning- AI and data mining to co-develop the clinical diagnostic algorithm for Novigenix’s LITOseek platform
- Novigenix’s LITOseek platform is a blood Immuno-Transcriptomic sequence platform- analyzing the gene expression modifications induced by the host as the response to triggers like onset of the cancer
Click here to read full press release/ article | Ref: Businesswire | Image: Novigenix
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com